How many years does it usually take to take Riboxil/Calilon?

As a targeted drug, Ribociclib is mainly used to treat HR-positive, HER2-negative advanced breast cancer, especially in combination with tamoxifen or aromatase inhibitors in adjuvant therapy. Riboxiclib prevents tumor cell proliferation by inhibiting the activity ofCDK4/6, thereby effectively inhibiting tumor growth and metastasis. For patients with early-stage breast cancer, the length of treatment with reboxil usually depends on the patient's condition and response to treatment.

For patients with early-stage breast cancer, the standard treatment cycle of ribociclib is generally3 years, which is also the treatment duration in most clinical practices. The specific treatment duration may be adjusted based on the patient's individual circumstances. For example, if a patient does not experience disease recurrence during treatment and does not experience unacceptable toxicities, doctors typically recommend continuing treatment with reboxil for three years. However, treatment may be discontinued early if the patient experiences significant side effects during treatment or if the disease relapses.

In theKISQALI clinical trial, the treatment duration for patients with early-stage breast cancer is usually 3 years, with the purpose of maximizing tumor growth suppression and preventing recurrence during this period. Criteria for ending treatment are usually that disease recurrence has not occurred and that the drug is well tolerated by the patient. However, if a patient experiences disease recurrence during treatment or develops unacceptable toxicity, treatment may be discontinued or the dose adjusted. :

For some patients, if the treatment effect is significant within 3 years and there is no recurrence of the disease, the doctor may evaluate whether to continue treatment or switch drugs based on the patient's specific situation. Clinically, individualized treatment is an important principle in the treatment of breast cancer. Therefore, decisions about the length and specific regimen of treatment should be based on the patient's health status, response to treatment, and physician's assessment.

Reference materials:https://us.kisqali.com/